These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1655 related articles for article (PubMed ID: 16461817)

  • 1. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?
    Ellenbogen KA; Levine JH; Berger RD; Daubert JP; Winters SL; Greenstein E; Shalaby A; Schaechter A; Subacius H; Kadish A;
    Circulation; 2006 Feb; 113(6):776-82. PubMed ID: 16461817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implantable cardioverter defibrillators and quality of life: results from the defibrillators in nonischemic cardiomyopathy treatment evaluation study.
    Passman R; Subacius H; Ruo B; Schaechter A; Howard A; Sears SF; Kadish A
    Arch Intern Med; 2007 Nov; 167(20):2226-32. PubMed ID: 17998496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study.
    Olshansky B; Poole JE; Johnson G; Anderson J; Hellkamp AS; Packer D; Mark DB; Lee KL; Bardy GH;
    J Am Coll Cardiol; 2008 Apr; 51(13):1277-82. PubMed ID: 18371559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy.
    Goldberger JJ; Subacius H; Schaechter A; Howard A; Berger R; Shalaby A; Levine J; Kadish AH;
    J Am Coll Cardiol; 2006 Sep; 48(6):1228-33. PubMed ID: 16979011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
    Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
    J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided Interventions and Implantable Cardioverter-defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death.
    Lau EW; Griffith MJ; Pathmanathan RK; Ng GA; Clune MM; Cooper J; Marshall HJ; Forsey PR; Stafford PJ; Gray RG; Skehan JD; Garratt CJ
    Europace; 2004 Jul; 6(4):257-66. PubMed ID: 15172648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex differences in outcome after implantable cardioverter defibrillator implantation in nonischemic cardiomyopathy.
    Albert CM; Quigg R; Saba S; Estes NA; Shaechter A; Subacius H; Howard A; Levine J; Kadish A;
    Am Heart J; 2008 Aug; 156(2):367-72. PubMed ID: 18657670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia.
    Corrado D; Calkins H; Link MS; Leoni L; Favale S; Bevilacqua M; Basso C; Ward D; Boriani G; Ricci R; Piccini JP; Dalal D; Santini M; Buja G; Iliceto S; Estes NA; Wichter T; McKenna WJ; Thiene G; Marcus FI
    Circulation; 2010 Sep; 122(12):1144-52. PubMed ID: 20823389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results.
    Wathen MS; DeGroot PJ; Sweeney MO; Stark AJ; Otterness MF; Adkisson WO; Canby RC; Khalighi K; Machado C; Rubenstein DS; Volosin KJ;
    Circulation; 2004 Oct; 110(17):2591-6. PubMed ID: 15492306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ventricular arrhythmia inducibility predicts subsequent ICD activation in nonischemic cardiomyopathy patients: a DEFINITE substudy.
    Daubert JP; Winters SL; Subacius H; Berger RD; Ellenbogen KA; Taylor SG; Schaechter A; Howard A; Kadish A;
    Pacing Clin Electrophysiol; 2009 Jun; 32(6):755-61. PubMed ID: 19545338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
    Noseworthy PA; Rosenberg MA; Fifer MA; Palacios IF; Lowry PA; Ruskin JN; Sanborn DM; Picard MH; Vlahakes GJ; Mela T; Das S
    Am J Cardiol; 2009 Jul; 104(1):128-32. PubMed ID: 19576333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
    Marín F; Gimeno JR; Payá E; García-Alberola A; Pérez-Alvarez L; Fernández X; de la Morena G; Sogorb F; Castro-Beiras A; Valdés M; Martínez JG; Monserrat L
    Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
    Connolly SJ; Hallstrom AP; Cappato R; Schron EB; Kuck KH; Zipes DP; Greene HL; Boczor S; Domanski M; Follmann D; Gent M; Roberts RS
    Eur Heart J; 2000 Dec; 21(24):2071-8. PubMed ID: 11102258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [14-year experience with implantable cardioverter/defibrillators: determination of prognosis and discharge behavior].
    Vester EG; Dees H; Dobran I; Hennersdorf M; Perings C; Heydthausen M; Winter J; Strauer BE
    Z Kardiol; 2000; 89 Suppl 3():194-205. PubMed ID: 10810803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ABCD (Alternans Before Cardioverter Defibrillator) Trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention.
    Costantini O; Hohnloser SH; Kirk MM; Lerman BB; Baker JH; Sethuraman B; Dettmer MM; Rosenbaum DS;
    J Am Coll Cardiol; 2009 Feb; 53(6):471-9. PubMed ID: 19195603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy -- dilemmas and difficulties.
    Przybylski A; Małecka L; Pytkowski M; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Ruzyłło W; Szwed H
    Kardiol Pol; 2005 Oct; 63(4):391-7; discussion 398. PubMed ID: 16273479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of implantable cardioverter defibrillator for primary vs secondary prevention of sudden death in patients with idiopathic dilated cardiomyopathy.
    Zecchin M; Di Lenarda A; Proclemer A; Faganello G; Facchin D; Petz E; Sinagra G
    Europace; 2004 Sep; 6(5):400-6. PubMed ID: 15294264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.
    Vieira AP; Adragão PP; Santos KR; Morgado FB; Cavaco DM; Rossi R; Abecasis M; Neves JP; Bonhosrst D; Gomes JL; Gomes RS
    Rev Port Cardiol; 2005 Mar; 24(3):407-15. PubMed ID: 15929624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of appropriate implantable cardioverter defibrillator (ICD) therapy in primary prevention patients with ischemic and nonischemic cardiomyopathy.
    Verma A; Sarak B; Kaplan AJ; Oosthuizen R; Beardsall M; Wulffhart Z; Higenbottam J; Khaykin Y
    Pacing Clin Electrophysiol; 2010 Mar; 33(3):320-9. PubMed ID: 19796352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy.
    McLeod CJ; Ommen SR; Ackerman MJ; Weivoda PL; Shen WK; Dearani JA; Schaff HV; Tajik AJ; Gersh BJ
    Eur Heart J; 2007 Nov; 28(21):2583-8. PubMed ID: 17483110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 83.